Search company, investor...


Founded Year



Acquired | Acquired



About Transpharma

TransPharma develops a transdermal drug delivery platform based on its RF-MicroChannel technology. This patented technology is employed in its clinically proven and commercially viable drug delivery system, ViaDerm. The ViaDerm system, designed for home use, aims to enable painless, needle-free, user-friendly delivery of drug compounds through the outer layer of the skin into the systemic circulation. a range of drug molecules from small to large molecules, such as peptides and proteins, may be administered using the ViaDerm system. The company's management team have experience in medical devices and pharmaceuticals development.In March 2012, Transpharma was acquired by Syneron Medical. The valuation of Transpharma was $3.6 million.

Headquarters Location

2 Yodfat St Northern Ind. Zone




Missing: Transpharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Transpharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Transpharma Patents

Transpharma has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Drug delivery devices, Routes of administration, Euphoriants, Piperidines


Application Date


Grant Date



Related Topics

Dosage forms, Drug delivery devices, Routes of administration, Euphoriants, Piperidines



Latest Transpharma News

Walden richt TransPharma International op

Jun 21, 2021

21 juni 2021 TransPharma International is een nieuwe naam in internationaal transport van goederen voor de farmaceutische industrie en gezondheidszorg. TransPharma International is ontstaan uit Movianto, dat een jaar geleden werd overgenomen door de Walden Group, een familiebedrijf met een omzet van 1,4 miljard euro. “Waldens groei op har markten heeft ertoe geleid dat het heeft geïnvesteerd in het versterken van zijn internationale aanbod en de groep heeft uitgebreide ervaring in temperatuurgecontroleerd transport en logistiek in lijn met goede distributiepraktijken. Met een wereldwijd aanbod, waaronder in-house beheer van douane- en handelsdiensten, een wegennet van meer dan 3.000 voertuigen, grensoverschrijdende expressdiensten en lucht- & zeevrachtexpeditie, brengt TransPharma International elementen van verschillende historische spelers van de groep – Eurotranspharma, Movianto, CSP – samen in een centraal beheerde bedrijfseenheid”, aldus Walden in een verklaring. De verandering stelt Walden in staat om zijn one-stop-shop aanbod voor de end-to-end healthcare supply chain te versterken, aldus Walden. David Evans, die aan het hoofd staat van de nieuwe business uni: “De oprichting van TransPharma International is een geweldige kans om Walden-klanten een beter antwoord te bieden op het gebied van wereldwijde vracht- en transportdiensten. We profiteren van een sterke ervaring van andere bedrijven in de groep die ons vertrouwen om de continuïteit in hun eerdere activiteiten te waarborgen en we zullen ons richten op het toevoegen van nieuwe waarde door te investeren in betrouwbare en krachtige IT-oplossingen om de kwaliteit en veiligheid van onze diensten te verbeteren.” TransPharma International heeft vestigingen in het Verenigd Koninkrijk, Frankrijk, België en ook in Nederland (Oss).

Transpharma Frequently Asked Questions (FAQ)

  • When was Transpharma founded?

    Transpharma was founded in 2000.

  • What is Transpharma's latest funding round?

    Transpharma's latest funding round is Acquired.

  • Who are the investors of Transpharma?

    Investors of Transpharma include Candela, Evergreen Venture Partners and Pitango Venture Capital.

  • Who are Transpharma's competitors?

    Competitors of Transpharma include Chiasma, MicroCHIPS Biotech, Corium International, OptiNose, NanoPass Technologies, Critical Pharmaceuticals, Ekos, Glide Pharma, Agentase, Pantec Biosolutions and 12 more.

Compare Transpharma to Competitors

NanoPass Technologies

NanoPass Technologies develops and commercializes painless intradermal (skin) delivery solutions for vaccines and large molecules. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.

Westfield Life Sciences Fund

Launched in July of 2000, the Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. Westfield's industry network developed by Mr. Muggia and his analytical team is critical to new idea generation.


Optotrack, Inc. is a high-tech company leading in the research and development of optical, imaging, chemical, as well as biological sensors and microsystems. The company is dedicated to commercializing its intellectual properties based on microfabrication and nanotechnology to seize rapidly growing market opportunities in the industries of healthcare, communication, and homeland security. Optotrack, Inc. offers a broad range of technology and business solutions from design through production to marketing and sales. The company combine decades of industry experience and R&D expertise in thin-film science, polymer engineering, solid-state sensing, digital imaging, optoelectronics, RF circuitry, medical diagnostics, microfluidics, and drug delivery to provide enabling technologies to the company's partners, customers, and community. The firm aims to deliver products and services of exceptional quality to cast the future, to improve the life quality for everyone.

Salvona Technologies Logo
Salvona Technologies

The mission statement of Salvona is to enhance people's quality of life through cutting-edge technology and the use of environmentally friendly materials and processes. Salvona has focused on developing new and advanced encapsulation and delivery systems to bridge technology gaps as well as to develop tools required to create new products that perform better, are cost effective and are environmentally friendly.

Felton International

Pulse NeedleFree Systems is a medical technology company focused on development of needle-free pharmaceutical injection systems for the animal health and human health industries. Pulse's animal health injection systems are marketed to large livestock producers in the United States and select international markets.


CapsuTech is a product driven company focused on research and development of semi-natural, peptide-based, polymers for drug targeting and encapsulation of various chemical and biological entities. Such entities might be drugs, cosmetics, vitamins, food additives, proteins, virions and even cells.nVarious combinations of CapsuTech's modified amino-acid building-blocks provide high-diversity population of polymers and thus enable to formulate almost all molecules and to meet wide spectrum of needs. Such needs include targeting, site-specific release, controlled release. Other characteristics include protection from pH, enzyme proteolysis, oxidation, light and other damaging factors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.